Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
67.7M
-
Number of holders
-
141
-
Total shares
-
74.3M
-
Shares change
-
+15.5M
-
Total reported value, excl. options
-
$553M
-
Value change
-
+$114M
-
Put/Call ratio
-
1.19
-
Number of buys
-
86
-
Number of sells
-
-45
-
Price
-
$7.45
Significant Holders of EyePoint Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (EYPT) as of Q4 2024
172 filings reported holding EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
EyePoint Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (EYPT) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.3M shares
.
Largest 10 shareholders include Cormorant Asset Management, LP (8.33M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (6.78M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.75M shares), BlackRock, Inc. (5.28M shares), FRANKLIN RESOURCES INC (4.14M shares), VANGUARD GROUP INC (3.8M shares), FEDERATED HERMES, INC. (3.71M shares), TCG Crossover Management, LLC (3.57M shares), RA CAPITAL MANAGEMENT, L.P. (3.18M shares), and CITADEL ADVISORS LLC (2.47M shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.